Printer Friendly

Oncolytics Biotech announces issuance of 23rd United States patent.

Oncolytics Biotech, Inc. (Calgary, Canada) has been granted United States Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus." The claims describe a method of using reovirus to prevent Ras-activated cancers from developing drug resistance to chemotherapeutic agents.

"Recent research conducted by the United States National Cancer Institute and Cornell University demonstrated that administering reovirus in combination with various chemotherapeutic agents potentiates, or enhances tumour-killing, thus preventing the cancer cells from developing drug resistance," said Dr. Matt Coffey, Chief Scientific Officer. "This patent complements the combination REOLYSIN and chemotherapy clinical program that we are pursuing in the U.K."

Oncolytics is focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.

Oncolytics Biotech, Inc.


COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Aug 1, 2007
Previous Article:Iowa State, Monsanto to collaborate on soybean technologies.
Next Article:Pressure BioSciences issued first patent in Canada.

Related Articles
Oncolytics issued Canadian reovirus patent.
Oncolytics announces issuance of third Canadian patent covering use of the reovirus to treat cancers.
Oncolytics announces issuance of second Canadian patent - therapeutic use of the reovirus for cellular proliferative disorders including cancer.
Oncolytics announces issuance of patent for reovirus clearance of ras-mediated neoplastic cells.
Oncolytics announces issuance of 15th United States patent.
Oncolytics Biotech announces issuance of 21th United States patent.
Oncolytics Biotech announces issuance of 6th Canadian patent.
Oncolytics Biotech announces issuance of 25th patent.
Oncolytics Biotech Announces Issuance of 8th Canadian Patent.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters